Abstract
Deaths are frequently under-estimated during emergencies, times when accurate mortality estimates are crucial for emergency response. This study estimates excess all-cause, pneumonia, and influenza mortality during the COVID-19 pandemic using the September 11, 2020 release of weekly mortality data from the United States (U.S.) Mortality Surveillance System (MSS) from September 27, 2015 to May 9, 2020, using semiparametric and conventional time-series models in 13 states with high reported COVID-19 deaths and apparently complete mortality data: California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, and Washington. We estimated greater excess mortality than official COVID-19 mortality in the U.S. (excess mortality 95% confidence interval (CI) (100013, 127501) vs. 78834 COVID-19 deaths) and 9 states: California (excess mortality 95% CI (3338, 6344) vs. 2849 COVID-19 deaths); Connecticut (excess mortality 95% CI (3095, 3952) vs. 2932 COVID-19 deaths); Illinois (95% CI (4646, 6111) vs. 3525 COVID-19 deaths); Louisiana (excess mortality 95% CI (2341, 3183) vs. 2267 COVID-19 deaths); Massachusetts (95% CI (5562, 7201) vs. 5050 COVID-19 deaths); New Jersey (95% CI (13170, 16058) vs. 10465 COVID-19 deaths); New York (95% CI (32538, 39960) vs. 26584 COVID-19 deaths); and Pennsylvania (95% CI (5125, 6560) vs. 3793 COVID-19 deaths). Conventional model results were consistent with semiparametric results but less precise. Significant excess pneumonia deaths were also found for all locations and we estimated hundreds of excess influenza deaths in New York.
We find that official COVID-19 mortality substantially understates actual mortality, excess deaths cannot be explained entirely by official COVID-19 death counts. Mortality reporting lags appeared to worsen during the pandemic, when timeliness in surveillance systems was most crucial for improving pandemic response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NSF OAC 1940179
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was not necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability: Data is publicly available but updated weekly. A copy of the data release is shared through GitHub.
Authors have no conflict of interest to report.
Covid-19 Pandemic Excess Mortality U.S.
Updated with latest release of death certificate data and according to feedback from reviewers.
Data Availability
Data comes from National Center for Health Statistics and is available to the public: https://gis.cdc.gov/grasp/fluview/mortality.html
